GSK to Acquire Nuvalent for $10.6 Billion, Boosting Oncology Pipeline with Late-Stage Lung Cancer Assets
GSK sits 41% above its 52-week low of $35.45.
Summary
GSK is acquiring Nuvalent for $10.6 billion, gaining late-stage oncology assets for lung cancer that are expected to significantly boost future sales and profits.
Key Events · M&A and Partnerships · GSK
-
Acquisition of Nuvalent
GSK will acquire Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on oncology, for an aggregate equity value of $10.6 billion.
-
Strategic Oncology Assets
The acquisition includes two late-stage, potential best-in-class ROS1 and ALK inhibitors (zidesamtinib and neladalkib) for non-small cell lung cancer, both currently under US FDA review for 2026 approvals.
-
Financial Impact
The deal is expected to be accretive to sales and core operating profit in 2027 and core EPS in 2029, with low single-digit percentage dilution to core EPS for 2026-2028.
-
Market Premium
The purchase price of $124 per share represents a 40% premium to Nuvalent's last closing price.
Analysis · GSK · Life Sciences
This acquisition significantly strengthens GSK's oncology pipeline by adding three lung cancer assets, including two late-stage, potential best-in-class inhibitors currently under FDA review. The $10.6 billion deal, representing a substantial portion of GSK's market capitalization, is a major strategic move expected to drive sales and core operating profit growth from 2027, despite minor near-term EPS dilution. It positions GSK for accelerated entry and expansion in the lung cancer market.
At the time of this filing, GSK was trading at $49.97 on NYSE in the Life Sciences sector, with a market capitalization of approximately $102.3B. The 52-week trading range was $35.45 to $61.70. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.